Tivic Health Shares Rise After US Agency Meeting on Entolimod Set

MT Newswires Live

2025/11/19

Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.

The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.

The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.

Entolimod has received Fast Track and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.

Price: 1.83, Change: +0.32, Percent Change: +21.56

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2584688369"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584688369\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584688369?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 03:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584688369","market":"nz","top_or_hot":-1,"title":"Tivic Health Shares Rise After US Agency Meeting on Entolimod Set","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.</p><p>The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.</p><p>The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.</p><p>Entolimod has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.</p><p>Price: 1.83, Change: +0.32, Percent Change: +21.56</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tivic Health Shares Rise After US Agency Meeting on Entolimod Set</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTivic Health Shares Rise After US Agency Meeting on Entolimod Set\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-19 03:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TIVC\">Tivic Health</a> Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.</p><p>The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.</p><p>The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.</p><p>Entolimod has received <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.</p><p>Price: 1.83, Change: +0.32, Percent Change: +21.56</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TIVC","symbol_name":"Tivic Health Systems, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2584688369","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584688369","pubTimestamp":1763493578,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiolo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TIVC":"Tivic Health Systems, Inc.","BK4082":"医疗保健设备"},"translate_title":"美国机构就恩托莫德举行会议后，Tivic Health股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TIVC":1},"content_text":"Tivic Health Systems (TIVC) shares rose 22% in recent Tuesday trading after the company secured an exclusive Techwatch meeting with the Biomedical Advanced Research and Development Authority's Radiological and Nuclear Medical Countermeasures Program staff.The company plans to present clinical data on Entolimod's effects in radiation-induced injury and acute radiation syndrome, alongside updates on manufacturing readiness and preparations for a Biologics License Application.The Techwatch format enables Tivic and authority staff to exchange technical information, set program priorities, and explore pathways for Entolimod's potential deployment in mass-casualty, stockpile, and field scenarios.Entolimod has received Fast Track and Orphan Drug designations from the US Food and Drug Administration, Tivic said Tuesday in a statement.Price: 1.83, Change: +0.32, Percent Change: +21.56","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}